423 related articles for article (PubMed ID: 22327882)
1. Targeting regulatory T cells.
Ménétrier-Caux C; Curiel T; Faget J; Manuel M; Caux C; Zou W
Target Oncol; 2012 Mar; 7(1):15-28. PubMed ID: 22327882
[TBL] [Abstract][Full Text] [Related]
2. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines.
Ruter J; Barnett BG; Kryczek I; Brumlik MJ; Daniel BJ; Coukos G; Zou W; Curiel TJ
Front Biosci (Landmark Ed); 2009 Jan; 14(5):1761-70. PubMed ID: 19273160
[TBL] [Abstract][Full Text] [Related]
3. Targeting regulatory T cells in tumors.
Liu C; Workman CJ; Vignali DA
FEBS J; 2016 Jul; 283(14):2731-48. PubMed ID: 26787424
[TBL] [Abstract][Full Text] [Related]
4. The interplay of effector and regulatory T cells in cancer.
Roychoudhuri R; Eil RL; Restifo NP
Curr Opin Immunol; 2015 Apr; 33():101-11. PubMed ID: 25728990
[TBL] [Abstract][Full Text] [Related]
5. Providence of the CD25
Chakraborty S; Bhattacharjee P; Panda AK; Kajal K; Bose S; Sa G
Immunol Cell Biol; 2018 Nov; 96(10):1035-1048. PubMed ID: 29768737
[TBL] [Abstract][Full Text] [Related]
6. CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer.
Wang RF
Hum Immunol; 2008 Nov; 69(11):811-4. PubMed ID: 18817828
[TBL] [Abstract][Full Text] [Related]
7. Targeted inhibition of IL-10-secreting CD25- Treg via p38 MAPK suppression in cancer immunotherapy.
Ohkusu-Tsukada K; Toda M; Udono H; Kawakami Y; Takahashi K
Eur J Immunol; 2010 Apr; 40(4):1011-21. PubMed ID: 20127675
[TBL] [Abstract][Full Text] [Related]
8. Disarming suppressor cells to improve immunotherapy.
Whiteside TL
Cancer Immunol Immunother; 2012 Feb; 61(2):283-288. PubMed ID: 22146892
[TBL] [Abstract][Full Text] [Related]
9. Challenges and future perspectives of T cell immunotherapy in cancer.
de Aquino MT; Malhotra A; Mishra MK; Shanker A
Immunol Lett; 2015 Aug; 166(2):117-33. PubMed ID: 26096822
[TBL] [Abstract][Full Text] [Related]
10. Roles of regulatory T cells in cancer immunity.
Takeuchi Y; Nishikawa H
Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
[TBL] [Abstract][Full Text] [Related]
11. Effect of pembrolizumab on CD4
Toor SM; Sasidharan Nair V; Pfister G; Elkord E
Clin Exp Immunol; 2019 Jun; 196(3):345-352. PubMed ID: 30693485
[TBL] [Abstract][Full Text] [Related]
12. Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine.
Kumagai S; Itahashi K; Nishikawa H
Nat Rev Clin Oncol; 2024 May; 21(5):337-353. PubMed ID: 38424196
[TBL] [Abstract][Full Text] [Related]
13. Treg Fragility: A Prerequisite for Effective Antitumor Immunity?
Overacre-Delgoffe AE; Vignali DAA
Cancer Immunol Res; 2018 Aug; 6(8):882-887. PubMed ID: 30068755
[TBL] [Abstract][Full Text] [Related]
14. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function.
Kim HR; Park HJ; Son J; Lee JG; Chung KY; Cho NH; Shim HS; Park S; Kim G; In Yoon H; Kim HG; Jung YW; Cho BC; Park SY; Rha SY; Ha SJ
J Immunother Cancer; 2019 Dec; 7(1):339. PubMed ID: 31801611
[TBL] [Abstract][Full Text] [Related]
15. Role for the cAMP-protein kinase A signaling pathway in suppression of antitumor immune responses by regulatory T cells.
Yaqub S; Taskén K
Crit Rev Oncog; 2008; 14(1):57-77. PubMed ID: 19105570
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of Cancer by Targeting Regulatory T cells.
Chen BJ; Zhao JW; Zhang DH; Zheng AH; Wu GQ
Int Immunopharmacol; 2022 Mar; 104():108469. PubMed ID: 35008005
[TBL] [Abstract][Full Text] [Related]
17. Exploiting regulatory T-cell populations for the immunotherapy of cancer.
van der Vliet HJ; Koon HB; Atkins MB; Balk SP; Exley MA
J Immunother; 2007 Sep; 30(6):591-5. PubMed ID: 17667522
[TBL] [Abstract][Full Text] [Related]
18. T regulatory cells in cancer: recent advances and therapeutic potential.
Elkord E; Alcantar-Orozco EM; Dovedi SJ; Tran DQ; Hawkins RE; Gilham DE
Expert Opin Biol Ther; 2010 Nov; 10(11):1573-86. PubMed ID: 20955112
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide inhibits the generation and function of CD8(+) regulatory T cells.
Traverso I; Fenoglio D; Negrini S; Parodi A; Battaglia F; Kalli F; Conteduca G; Tardito S; Traverso P; Indiveri F; Filaci G
Hum Immunol; 2012 Mar; 73(3):207-13. PubMed ID: 22285846
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic prospects of targeting myeloid-derived suppressor cells and immune checkpoints in cancer.
Toor SM; Elkord E
Immunol Cell Biol; 2018 Oct; 96(9):888-897. PubMed ID: 29635843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
